SCHEMBL5743354

SCHEMBL5743354

O=C(Cc1cc(I)c(Oc2ccccc2)c(I)c1)NO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCNA P12004 10/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
THRA P10827 4/20 0.51
THRB P10828 4/20 0.51
PPARG P37231 3/20 0.51
RXRA P19793 2/20 0.51
ITGB3 P05106 1/20 0.51
ITGAV P06756 1/20 0.51
POLB P06746 2/20 0.51
HIF1A Q16665 2/20 0.51
ABCB11 O95342 1/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
PGR P06401 1/20 0.51
CHRM2 P08172 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5743343 0.87 PCNA (0.62) PCNATHRATHRBPPARGRXRA
SCHEMBL5742010 0.86 PCNA (0.57) PCNAHDAC8THRATHRBPPARG
SCHEMBL5740828 0.82 THRB (0.57) MEN1KMT2AHDAC8HDAC6THRA
SCHEMBL5742720 0.81 HDAC8 (0.56) PCNAMEN1KMT2AHDAC8HDAC6
SCHEMBL5740650 0.80 HDAC6 (0.47) PCNAMEN1KMT2AHDAC8HDAC6
SCHEMBL5743137 0.77 CYP1A2 (0.50) PCNAKMT2AHDAC6THRATHRB
SCHEMBL16124459 0.74 PCNA (0.76) PCNATHRATHRBPPARGRXRA
SCHEMBL16124455 0.74 PCNA (0.70) PCNAMEN1KMT2ATHRATHRB
SCHEMBL16124438 0.74 PCNA (0.70) PCNAMEN1KMT2ATHRATHRB
SCHEMBL5742613 0.73 PCNA (0.74) PCNATHRATHRBPPARGRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP claimed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US claimed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP claimed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO claimed
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP disclosed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US disclosed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP disclosed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267015-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 PCNA 1541/4885MEN1 2559/4885KMT2A 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.